When the tumor progressed after five lines of TKIs, the patient was treated with a TRK inhibitor (larotrectinib) for 4 months and had an ongoing partial response (44%) according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.114. The gene discussed is NTRK1; the disease is neoplasm.